Skip to main content
. Author manuscript; available in PMC: 2024 Nov 29.
Published in final edited form as: Mol Pharm. 2023 Aug 8;20(9):4629–4639. doi: 10.1021/acs.molpharmaceut.3c00360

Figure 3.

Figure 3.

Cell binding studies evaluating [89Zr]Zr-DFO-2Rs15d. (A) Cell binding and specificity studies show [89Zr]Zr-DFO-2Rs15d has specific binding to HER2 while binding to a different epitope than trastuzumab. (n = 8 for each group) (B) Internalization studies showed a steady increase of cell-associated [89Zr]Zr-DFO-2Rs15d internalized over 72 h. (n = 6 for each group) **p < 0.01 and ****p < 0.0001.